Jessica Liliana Vargas-Neri

Jessica Liliana Vargas-Neri


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2022 in Pharmacogenomics
Verified
Journal Article
Closed access
JVJessica Liliana Vargas-Neri
Jessica Liliana Vargas-Neri
BCBruce Carleton
Bruce Carleton
CRColin J Ross
Colin J Ross
MMMara Medeiros
Mara Medeiros
GCGilberto Castañeda-Hernandez
Gilberto Castañeda-Hernandez
PCPatricia Clark
Patricia Clark
Background: The aim of this study was to evaluate the association between well-defined genetic risk variants in SLC28A3, RARG and UGT1A6 and anthracycline-induced cardiotoxicity in Mexican pediatri...

27 September 2024 in Pharmacy
Verified
Journal Article
Open access
PDF file
DBDulce D. Blanco-Vega
Dulce D. Blanco-Vega
ALALFONSO REYES LOPEZ
ALFONSO REYES LOPEZ
JVJessica Liliana Vargas-Neri
Jessica Liliana Vargas-Neri
FOFrida I. Osnaya-Valencia
Frida I. Osnaya-Valencia
In Mexico, type 2 diabetes mellitus (T2DM) is a serious public health concern. As experts in drug therapy, pharmacists are essential additions to multidisciplinary diabetes patient care teams. There have been no systematic reviews or meta-analyses performed on pharmacist-led interventions (PIs) in Mexico; therefore, the impact of PIs on patients remains poorly explored. An electronic search of the PubMed, SciELO and BVS databases and certain institutional repositories was conducted in English and Spanish through 24 August 2021 with a subsequent update through June 2024. A total of 1302 potentially relevant studies were identified in the initial search, of which nine met the eligibility criteria and were included in this systematic review. The results suggest that PIs, such as pharmacotherapeutic follow-up and patient education, may have positive effects on outcomes in Mexican patients with T2DM. PIs led to significant reductions in glycosylated hemoglobin, fasting blood glucose, triglycerides, total cholesterol, LDL cholesterol and arterial blood pressure levels, general reductions in body mass index and negative outcomes associated with medication, as well as significant improvements in therapeutic adherence and patient knowledge in the intervention group during follow-up periods of 3–12 months. Further well-designed research, including controlled studies with adequate sample sizes and standardized tools, is essential to fully understand the effects of PIs regarding patients with T2DM in Mexico.

18 September 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
APAna Mayra Pérez-Morales
Ana Mayra Pérez-Morales
RJRodolfo Norberto Jiménez-Juárez
Rodolfo Norberto Jiménez-Juárez
OMOlga Magdala Morales-Ríos
Olga Magdala Morales-Ríos
ALALFONSO REYES LOPEZ
ALFONSO REYES LOPEZ
PCPatricia Clark
Patricia Clark
TAthe Group of Collaboration ASP-HIM
the Group of Collaboration ASP-HIM
Background: During the coronavirus disease 2019 (COVID-19) pandemic, pediatric inpatients frequently received at least one antibiotic, and several antimicrobial stewardship programs (ASPs) strategies were disrupted. In Mexico, no published data are available on antibacterial consumption in children. The aim of this study was to evaluate antibacterial consumption levels and trends before, during, and after the COVID-19 pandemic in a tertiary care pediatric hospital in Mexico, and to forecast future antibacterial consumption. Methods: This was a secondary analysis based on time series data of monthly antibacterial consumption from January 2016 to June 2024 in a tertiary care pediatric hospital. Antibacterial consumption was retrospectively measured for the pre-pandemic, pandemic, and post-pandemic periods. Consumption was expressed as days of therapy (DOT) per 1000 patient-days (pd). Results: The mean antibacterial consumption at the Hospital Infantil de México Federico Gómez (HIMFG) from 2016 to 2024 was 789.3 (95% CI, 756.1–822.5) DOT/1000 pd. In the medical pediatric intensive care unit (M-PICU) and surgical pediatric intensive care unit (S-PICU), mean consumption was 1305.3 DOT/1000 pd (95% CI: 1119.1–1491.6) and 1634.5 DOT/1000 pd (95% CI: 1444.2–1824.9), respectively. Before the pandemic, the hospital-wide mean consumption was 848.8 DOT/1000 pd (95% CI: 811.3–886.2); during the pandemic, it was 709.6 DOT/1000 pd (95% CI: 650.3–769.0); and after the pandemic, 799.2 DOT/1000 pd (95% CI: 698.1–900.3). Overall, consumption rates oscillated around the mean, and no patterns were observed. Conclusions: The COVID-19 pandemic did not affect trends of antibacterial consumption across the hospital or in the pediatric intensive care unit. Although the prior authorization component of the ASP maintained antibacterial consumption around the mean, the implementation of additional ASP strategies -such as education and persuasive interventions- alongside current restrictive measures may help further optimize antibacterial consumption in pediatric units.

2 June 2023 in Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
JPJosé Fernando Pérez-Franco
José Fernando Pérez-Franco
GHGabriela Hernández-Pliego
Gabriela Hernández-Pliego
JJJocelyn Jacobo-Mendoza
Jocelyn Jacobo-Mendoza
VMVanessa Karina Martínez-Lara
Vanessa Karina Martínez-Lara
LJLuis Juárez
Luis Juárez
JVJessica Liliana Vargas-Neri
Jessica Liliana Vargas-Neri
Late adverse events (LAEs) are an important cause of illness and disability in childhood cancer survivors (CCSs) and increase the risk of mortality. The aim of this cross-sectional study was to describe the frequency and severity of treatment-related LAEs in Mexican CCSs. The study period was between September 2018 and April 2019. We tested a sample of 82 CCSs at the Hospital Infantil de México Federico Gómez. We considered an LAE to be any medical effect related to treatment after ending cancer therapy. All LAEs were classified according to severity (using the grades of Common Terminology Criteria for Adverse Events v.5.0), diagnosis and time of occurrence after treatment. The treatment-related LAE frequency was 11.0% (95% CI; 4.2–17.8%). A total of 11 LAEs were identified in nine patients. Slightly over half of the patients were male (54.9%). The most frequent diagnosis was acute lymphoblastic leukemia (45.1%). The body systems involved in LAEs were the endocrine (55.6%), neurological (22.2%), auditory (11.1%) and renal (11.1%) systems. Obesity was the most frequent LAE (45.4%). Most LAEs were classified as grade 1 and 2 (60%). The median follow-up was 6.5 years. The odds ratio was used as a measure of association to identify characteristics associated with the LAEs. We identified that the age at diagnosis (OR = 0.71, 95% CI, 0.51–0.99; p = 0.046) and chemotherapy-only group (OR = 0.03, 95% CI, 0.00–0.86, p = 0.040) were associated with LAEs. This is the first study that describes the frequency and severity of LAEs in Mexican childhood cancer survivors.

18 April 2019 in Latin american journal of clinical sciences and medical technology
Verified
Journal Article
Open access
ZMZeltzin Maya-Díaz
Zeltzin Maya-Díaz
JVJessica Liliana Vargas-Neri
Jessica Liliana Vargas-Neri
LCLuis Carbajal-Rodríguez
Luis Carbajal-Rodríguez
MNMaría del Socorro Negrete-Paz
María del Socorro Negrete-Paz
GCGilberto Castañeda-Hernandez
Gilberto Castañeda-Hernandez
At present, Mexico has a sound regulation for biocomparables or biosimilars. Notwithstanding, as in other countries, the regulation for biosimilar orphan medicines remains a grey area, as there is no clear path for their development and evaluation. This situation has allowed the commercialization of non - innovator orphan medicines that do not meet biocomparability criteria, with the consequent risk for patients. This was the case of Asbroder®, an intended copy of imiglucerase that was marketed in Mexico in 2015 but then withdrawn in 2020. This article discusses the limitations in the regulation of biosimilar orphan medicines and the pharmacovigilance activities required to ensure patient safety, emphasizing replacement therapies with recombinant enzymes. Our purpose is to provide elements of discussion allowing the generation of adequate regulation for biosimilar orphan medicines. Health authorities are advised to consider these aspects to create regulations ensuring biosimilar orphan drugs' quality, efficacy, and safety.

21 March 2026 in Drug Safety
Verified
Journal Article
Open access
PDF file
JVJessica Liliana Vargas-Neri
Jessica Liliana Vargas-Neri
ACAngela Caro-Rojas
Angela Caro-Rojas
GCGilberto Castañeda-Hernandez
Gilberto Castañeda-Hernandez
CCChristian Camilo Cuello-Meza
Christian Camilo Cuello-Meza
BDBetty Duarte
Betty Duarte
LTLuz Dary Terán-Mercado
Luz Dary Terán-Mercado
Pharmacovigilance in Latin America has witnessed notable progress in recent years, marked by advancements in regulatory frameworks, regional cooperation, and increased academic involvement. However, heterogeneity among countries, uneven institutional development, and limited resources still hinder its full impact on public health. In this context, the Latin American Chapter of the International Society of Pharmacovigilance (ISoP LATAM) has played a key role in organizing two regional symposia: Cartagena, Colombia (2023), and Merida, Mexico (2025). Through multidisciplinary roundtables and open forums, ISoP LATAM has brought together regulators, academia, healthcare professionals, researchers, patient organizations, and industry representatives to promote dialogue, identify opportunities, and propose measures to improve pharmacovigilance in the region. Discussion included regulatory harmonization and convergence, the adoption of international standards for risk management and safety reporting, and the integration of artificial intelligence and real-world evidence into pharmacovigilance systems. Participants emphasized the importance of addressing medication errors through a Human Factors/Ergonomics approach, strengthening the monitoring and regulation of biosimilars, and creating differentiated frameworks for recognizing therapeutic failures. The expansion of pharmaceutical care and the systematic inclusion of pharmacovigilance education across the health sciences’ curriculum were highlighted as priorities. The reflections from these symposia emphasize the crucial role of ISoP LATAM in providing a platform for open and multidisciplinary discussions. Shifting the focus from solely regulatory topics to a broader public health perspective and expanding the agenda to include emerging fields such as pharmacogenomics, ecopharmacovigilance, and patient engagement—while ensuring fair access to technological innovations—will be vital for enhancing drug safety in Latin America.